2018
Forecasting Hepatitis C liver disease burden on real‐life data. Does the hidden iceberg matter to reach the elimination goals?
Kondili LA, Robbins S, Blach S, Gamkrelidze I, Zignego A, Brunetto M, Raimondo G, Taliani G, Iannone A, Russo F, Santantonio T, Zuin M, Chessa L, Blanc P, Puoti M, Vinci M, Erne E, Strazzabosco M, Massari M, Lampertico P, Rumi M, Federico A, Orlandini A, Ciancio A, Borgia G, Andreone P, Caporaso N, Persico M, Ieluzzi D, Madonia S, Gori A, Gasbarrini A, Coppola C, Brancaccio G, Andriulli A, Quaranta M, Montilla S, Razavi H, Melazzini M, Vella S, Craxì A, Group P. Forecasting Hepatitis C liver disease burden on real‐life data. Does the hidden iceberg matter to reach the elimination goals? Liver International 2018, 38: 2190-2198. PMID: 29900654, PMCID: PMC6282782, DOI: 10.1111/liv.13901.Peer-Reviewed Original ResearchConceptsHCV elimination goalsElimination goalsBirth cohortHCV-endemic countriesLiver disease burdenCare scenariosHigh prevalence groupPublic health initiativesEligible patientsAntiviral treatmentPrevalence groupDisease burdenViraemic infectionsBurden estimatesEndemic countriesPatientsCare individualsHealth initiativesAbstractTextTreatment ratesCohortScreening strategyEligible poolTreatmentPotential strategy
2017
Direct‐acting antivirals combination for elderly patients with chronic hepatitis C: A cost‐effectiveness analysis
Ciaccio A, Cortesi PA, Bellelli G, Rota M, Conti S, Okolicsanyi S, Rota M, Cesana G, Mantovani LG, Annoni G, Strazzabosco M. Direct‐acting antivirals combination for elderly patients with chronic hepatitis C: A cost‐effectiveness analysis. Liver International 2017, 37: 982-994. PMID: 27943549, DOI: 10.1111/liv.13339.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAntiviral AgentsComputer SimulationCost-Benefit AnalysisDecision Support TechniquesDisease ProgressionDrug CostsDrug Therapy, CombinationFemaleFrail ElderlyGeriatric AssessmentHepatitis C, ChronicHumansLiver CirrhosisMaleMarkov ChainsModels, EconomicQuality-Adjusted Life YearsRisk FactorsTime FactorsTreatment OutcomeConceptsIncremental cost-effectiveness ratioChronic hepatitis CQuality-adjusted life yearsCost-effectiveness ratioElderly patientsCHC patientsHepatitis CFrailty phenotypeFrailty statusFibrosis stageLife yearsElderly CHC patientsMild fibrosis stageInterferon-free treatmentHealthcare system perspectiveLifetime time horizonCost-effectiveness analysisDAA treatmentDAA combinationsAdvanced fibrosisFrail subjectsClinical variablesLiver fibrosisF2 patientsAge 75